Global Stem Cell Umbilical Cord Blood Market 2015-2019
About Stem Cell UCB
UCB is the blood that remains in the placenta and the attached umbilical cord after childbirth. UCB contains stem cells that are unique, smart, and are capable of treating several life-threatening diseases. They are used in the treatment of hematopoietic and genetic disorders. The placental blood can produce 10 times more quantity of stem cells compared to the umbilical cord, which can in turn be used for the treatment of an adult patient. The cord blood that is collected during the childbirth is stored and cryopreserved. The storage of the cord blood can be done at private cord blood banks or public cord blood banks. This preserved blood can be used for the transplantation, and treatment of diseases at the later stages of life.
Technavio's analysts forecast the global stem cell UCB market to grow at a CAGR of 30.36% over the period 2014-2019.
Covered in this Report
The report covers the present scenario and the growth prospects of the global stem cell UCB market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the banking and utilization of UCB stem cells for the treatment of various disorders, such as cancers, blood disorders, metabolic disorders, immune diseases, and others.
Technavio's report, Global Stem Cell UCB Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global stem cell UCB market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.Key Regions
Technavio Announces the Publication of its Research Report – Global Stem Cell Umbilical Cord Blood (UCB) Market 2015-2019
Technavio recognizes the following companies as the key players in the Global Stem Cell Umbilical Cord Blood Market: Caladrius Biosciences, Celgene, Mesoblast and Pluristem Therapeutics
Other Prominent Vendors in the market are: Athersys, CHA Bio & Diostech, Cytori Therapeutics, Nuo Therapeutics, Ocata Therapeutics, Opexa Therapeutics, Osiris Therapeutics, Teva Pharmaceuticals and United Therapeutics
Commenting on the report, an analyst from Technavio’s team said: “Public awareness of stem cell UCB banking is increasing due to the various awareness programs conducted. This is done with the motive of making people aware of the potential benefits of cord blood banking. It will result in social and economic benefits as well. At the events, the idea is to educate people about the importance of cord blood banking. This is vital because it can help in the improvement of the quality of life of many patients suffering from life-threatening diseases. Companies such as Americord and Viacord are promoting July as National Stem Cell Awareness month. Similarly, Precious Cells surveyed 1,000 families in UK with children under the age of 10, as part of the National Stem Cell Awareness Day on October 8, 2014. To increase the awareness of cord blood banking, Save the Cord Foundation is partnering with Bioinformant. Also, LifeCell is creating awareness among in India about the need for umbilical cord stem cell banking. These programs help in promoting awareness for present and future stem cell treatments.”
According to the report, UCB stem cells prove to be an effective treatment option for more than 80 diseases, such as cancer, immunodeficiency disorders, and blood disorders. Many of these diseases, which have no cure, can be treated effectively with the use of stem cells obtained from the umbilical cord. These stem cells travel to the site of damage and identify the defective cells. They then initiate a healing process and are thus used in the treatment. Since they are derived from the same individual, the risk of rejection can also be eliminated. Research is being carried out for the development of UCB stem cells as an effective treatment option for diseases such as diabetes, Alzheimer's disease, brain tumor, and heart failure. They can thus be used as a successful mode of treatment for many of life-threatening diseases.
Further, the report states that accreditations and stringent rules may pose a challenge, as not all hospitals will be able to collect and store the cord blood.
Caladrius Biosciences, Celgene, Mesoblast, Pluristem Therapeutics, Athersys, CHA Bio & Diostech, Cytori Therapeutics, Nuo Therapeutics, Ocata Therapeutics, Opexa Therapeutics, Osiris Therapeutics, Teva Pharmaceuticals, United Therapeutics